Vanguard Group
PVCT

Vanguard Group’s PROVECTUS BIOPHARMACEUTICALS, INC. (DE) PVCT Stock Holding History

Vanguard Group’s Portfolio PVCT Stock Details PVCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-3,693,146
Closed -$366K – 4140
2016
Q3 		$366K Sell
3,693,146
-37,032
-1% -$8.08K ﹤0.01% 3814
2016
Q2 		$1.38M Buy
3,730,178
+5,800
+0.2% +$2.21K ﹤0.01% 3510
2016
Q1 		$1.41M Buy
3,724,378
+464,700
+14% +$191K ﹤0.01% 3492
2015
Q4 		$1.27M Buy
3,259,678
+102,101
+3% +$48.4K ﹤0.01% 3548
2015
Q3 		$1.82M Buy
3,157,577
+58,421
+2% +$29.9K ﹤0.01% 3419
2015
Q2 		$1.67M Hold
3,099,156
– – ﹤0.01% 3482
2015
Q1 		$2.53M Hold
3,099,156
– – ﹤0.01% 3311
2014
Q4 		$2.48M Buy
3,099,156
+137,900
+5% +$126K ﹤0.01% 3202
2014
Q3 		$3.02M Buy
+2,961,256
New +$2.87M ﹤0.01% 3097

Other funds holding PVCT

CCB
Cutter & Co Brokerage Ballwin, Missouri $423M AUM 15.02% 1-Year Est. Return
HFBOT
Home Federal Bank of Tennessee Knoxville, Tennessee $463M AUM 24.62% 1-Year Est. Return

Vanguard Group's PVCT Position: Q4 2016 in Review

Vanguard Group sold out of PROVECTUS BIOPHARMACEUTICALS, INC. (DE) (PVCT) in Q4 2016, closing a stake of 3,693,146 shares — an estimated $366K sold.

Vanguard Group first reported a position in PVCT in Q3 2014 and held it in 9 quarters. The position peaked at $3.02M in Q3 2014. 8 funds tracked by Wall St. Rank hold PVCT as of Q4 2016.

  • Vanguard Group reported no remaining PROVECTUS BIOPHARMACEUTICALS, INC. (DE) position as of Q4 2016 after selling out during the quarter.
  • Vanguard Group sold 3,693,146 PROVECTUS BIOPHARMACEUTICALS, INC. (DE) shares in Q4 2016, an estimated $366K.
  • Vanguard Group first reported a position in PROVECTUS BIOPHARMACEUTICALS, INC. (DE) in Q3 2014 and held it in 9 quarters.
  • Vanguard Group's PROVECTUS BIOPHARMACEUTICALS, INC. (DE) position peaked at $3.02M in Q3 2014.
  • 8 funds tracked by Wall St. Rank held PROVECTUS BIOPHARMACEUTICALS, INC. (DE) as of Q4 2016.

Based on Vanguard Group's 13F filing for Q4 2016, filed 14 Feb 2017.